BrightRock Gold Corp (BRGC)

[langlui]

NFRM News March 18th:

National Pharmaceuticals Corp. in Association With Globe Labs to Enter Into Discussion on Clinical Trials Protocols for GLB333
Friday March 18, 2011, 8:05 am EDT

MIAMI, FLORIDA--(Marketwire - 03/18/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" announced today that in conjunction with Globe Laboratories have identified a contract research organization (CRO) from Europe to develop protocols for clinical trials of GLB333. Parties have decided that the Clinical Investigations group from Vienna, Austria would be most suitable for conducting the Phase I clinical trials. The trials which would be the first for GLB333 shall focus on the ability of the drug to speed up wound healing in diabetes patients suffering from chronic wound and tissue efflux.

"We are pleased to have this critical step initiated to identify and potentially engage a strong and experienced CRO group to advise us and conduct the necessary work with our drug for proof of efficacy and performance", said Elaine Affleck, President of National Pharmaceuticals Corp.